Prosensa Holding B.V. (RNA) 5.07 $RNA
Why Investors Need to Watch Sarepta Therapeutics Inc.
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Tue Apr 15, 8:30AM CDT
Sarepta is a popular stock in the Fool community, but its inestors have had a tough run lately, watching shares lose half of their value in the past six months. A late-stage trial failure by a competing drug from GlaxoSmithKline and Prosensa ...
Prosensa to Appoint Michael Wyzga to Supervisory Board
GlobeNewswire - Tue Apr 08, 8:40AM CDT
Prosensa Holding N.V. (NASDAQ: RNA), the Dutch biopharmaceutical company focusing on rare diseases with a high unmet medical need, today announced that Michael S. Wyzga has been nominated for appointment to its Supervisory Board at the next shareholders' meeting, scheduled for June 17, 2014.
Morning Movers in Biotech: Agenus Inc., GlaxoSmithKline plc and Synta Pharmaceuticals Corp.
George Budwell, The Motley Fool - Motley Fool - Thu Mar 20, 8:17AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at the top stories in biotech and health...
Prosensa Rises on Encouraging Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 19, 4:20PM CDT
Shares of Prosensa rose following the announcement of encouraging data from a phase II study on drisapersen.
Prosensa rises on new data
at Investor's Business Daily - Tue Mar 18, 5:18PM CDT
The biotech shares rose 3.9% to 7.02 after the company released new data from a follow-up to a study of its Duchenne muscular dystrophy candidate late Mon. In Sept., Prosensa (RNA) said that after the initial treatment, the benefit of the drug failed...
Prosensa Muscular Dystrophy Data Send Stock Rising
at Investor's Business Daily - Tue Mar 18, 11:50AM CDT
Beleaguered biotech stock Prosensa (RNA) was up 8% in midday trading on the stock market today after the company reported new data on its Duchenne muscular dystrophy candidate late Monday. Earlier, Prosensa stock was up as much as 30%, to 8.80, a...
Prosensa Making the Best of Inconsistent Drisapersen Data
at The Street - Tue Mar 18, 10:03AM CDT
With its Big Pharma partner gone, Prosensa will probably try to conjure a good story to bring in front of the FDA.
Today’s Top Biotech Stories: Prosensa, Medivation, and Alcobra
Leo Sun, The Motley Fool - Motley Fool - Tue Mar 18, 8:26AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at this three top stocks -- Prosensa , ...
Prosensa Announces Full Year 2013 Financial Results and Recent Corporate Developments
Thomson Reuters ONE - Tue Mar 18, 6:01AM CDT
Prosensa Committed to Defining a Path Forward for Its Lead Product, Drisapersen
Prosensa Announces 48-Week Data from a U.S. Phase II Placebo-Controlled Study of Drisapersen in 51 DMD Boys
GlobeNewswire - Mon Mar 17, 5:00PM CDT
Prosensa Holding N.V. (NASDAQ: RNA), the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, today reported encouraging 48-week data from its U.S.-based, Phase II placebo-controlled study (DMD114876 or DEMAND V) of its lead compound, drisapersen, for the treatment of Duchenne Muscular Dystrophy (DMD).
What Lies Ahead For Sarepta Therapeutics, Inc.?
Brian Orelli, The Motley Fool - Motley Fool - Fri Mar 14, 1:30PM CDT
Sarepta Therapeutics has been one roller coaster of a stock over the last year while waiting for the Food and Drug Administration to make up its mind about whether its Duchenne muscular dystrophy drug, eteplirsen, deserves an accelerated approval....
Prosensa to Present at Upcoming Investor Conferences
GlobeNewswire - Thu Mar 06, 8:24AM CST
Prosensa Holding N.V. (NASDAQ: RNA) announced today announced presentations at upcoming investor conferences. Celia Economides, Senior Director, Investor Relations & Corporate Communications, will present a corporate overview at the ROTH Conference 2014 in Dana Point, California on Tuesday, March 11, at 10:30am (Pacific Time) and at the Barclays Healthcare Conference in Miami, Florida on Wednesday, March 12, at 1:30pm (Eastern Time).
Prosensa Holding N.V. to Webcast Conference Call Discussing Full Year 2013 Financial Results and Corporate Update on March 18, 2014
GlobeNewswire - Wed Mar 05, 9:18AM CST
Prosensa Holding N.V. (NASDAQ: RNA) today announced that the Company will host a conference call and live audio webcast on Tuesday, March 18, 2014 8:00am Eastern Time (1:00pm Central European Time) to report its full year 2013 financial results and provide a corporate update.
Why Sarepta Therapeutics Inc. Might Have a Fighting Chance
Brian Orelli, The Motley Fool - Motley Fool - Tue Mar 04, 5:30PM CST
In November, it looked like Sarepta Therapeutics had very little chance of getting an accelerated approval for its Duchenne muscular dystrophy drug eteplirsen. The company said the Food and Drug Administration did a 180, from being open to...
4 Biotech Stocks Under $10 Moving Higher
at The Street - Wed Feb 26, 5:00AM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
3 Biotech Stocks to Avoid: Amarin, Dendreon, and Prosensa
Leo Sun, The Motley Fool - Motley Fool - Mon Feb 17, 2:37PM CST
In the stock market, everyone loves a great turnaround story. In the biotech sector, where companies can rally or plunge by the double-digits on an FDA approval or rejection, bottom-fishing investors love to search for broken stocks with overlooked...
Shareholder Rights Law Firm Johnson & Weaver, LLP Announces Investigation of Prosensa Holding N.V. and Its Disclosures Related to Experimental Drug Drisapersen
Business Wire - Wed Feb 05, 3:45PM CST
Shareholder rights law firm Johnson & Weaver, LLP has commenced an investigation into whether certain officers and directors of Prosensa Holding N.V. (NASDAQ: RNA) violated state or federal laws. Prosensa is a Dutch biotechnology company engaged in the discovery and development of ribonucleic acid-modulating therapeutics for the treatment of genetic disorders.
Companies Limp Towards a Duchenne Treatment – Is There Hope of a Finish Line?
Amy Ho, The Motley Fool - Motley Fool - Tue Feb 04, 5:30PM CST
Duchenne's muscular dystrophy is a debilitating disease of young males resulting from an early stop sign (nonsense mutation) in an essential muscle protein dystrophin. While only 35,000 patients in the US and Europe are afflicted, the disease is so...
Prosensa to Participate at Upcoming Investor Conferences
GlobeNewswire - Fri Jan 31, 8:17AM CST
Prosensa Holding N.V. (NASDAQ: RNA) announced today that it is schedule to participate at the following investor conferences in February.
Why Investors Need to Watch Sarepta Therapeutics Inc.
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Tue Apr 15, 8:30AM CDT
Sarepta is a popular stock in the Fool community, but its inestors have had a tough run lately, watching shares lose half of their value in the past six months. A late-stage trial failure by a competing drug from GlaxoSmithKline and Prosensa ...
Prosensa to Appoint Michael Wyzga to Supervisory Board
GlobeNewswire - Tue Apr 08, 8:40AM CDT
Prosensa Holding N.V. (NASDAQ: RNA), the Dutch biopharmaceutical company focusing on rare diseases with a high unmet medical need, today announced that Michael S. Wyzga has been nominated for appointment to its Supervisory Board at the next shareholders' meeting, scheduled for June 17, 2014.
Morning Movers in Biotech: Agenus Inc., GlaxoSmithKline plc and Synta Pharmaceuticals Corp.
George Budwell, The Motley Fool - Motley Fool - Thu Mar 20, 8:17AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at the top stories in biotech and health...
Prosensa Rises on Encouraging Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 19, 4:20PM CDT
Shares of Prosensa rose following the announcement of encouraging data from a phase II study on drisapersen.
Prosensa rises on new data
at Investor's Business Daily - Tue Mar 18, 5:18PM CDT
The biotech shares rose 3.9% to 7.02 after the company released new data from a follow-up to a study of its Duchenne muscular dystrophy candidate late Mon. In Sept., Prosensa (RNA) said that after the initial treatment, the benefit of the drug failed...
Prosensa Muscular Dystrophy Data Send Stock Rising
at Investor's Business Daily - Tue Mar 18, 11:50AM CDT
Beleaguered biotech stock Prosensa (RNA) was up 8% in midday trading on the stock market today after the company reported new data on its Duchenne muscular dystrophy candidate late Monday. Earlier, Prosensa stock was up as much as 30%, to 8.80, a...
Prosensa Making the Best of Inconsistent Drisapersen Data
at The Street - Tue Mar 18, 10:03AM CDT
With its Big Pharma partner gone, Prosensa will probably try to conjure a good story to bring in front of the FDA.
Today’s Top Biotech Stories: Prosensa, Medivation, and Alcobra
Leo Sun, The Motley Fool - Motley Fool - Tue Mar 18, 8:26AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at this three top stocks -- Prosensa , ...
Prosensa Announces Full Year 2013 Financial Results and Recent Corporate Developments
Thomson Reuters ONE - Tue Mar 18, 6:01AM CDT
Prosensa Committed to Defining a Path Forward for Its Lead Product, Drisapersen
Prosensa Announces 48-Week Data from a U.S. Phase II Placebo-Controlled Study of Drisapersen in 51 DMD Boys
GlobeNewswire - Mon Mar 17, 5:00PM CDT
Prosensa Holding N.V. (NASDAQ: RNA), the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, today reported encouraging 48-week data from its U.S.-based, Phase II placebo-controlled study (DMD114876 or DEMAND V) of its lead compound, drisapersen, for the treatment of Duchenne Muscular Dystrophy (DMD).
What Lies Ahead For Sarepta Therapeutics, Inc.?
Brian Orelli, The Motley Fool - Motley Fool - Fri Mar 14, 1:30PM CDT
Sarepta Therapeutics has been one roller coaster of a stock over the last year while waiting for the Food and Drug Administration to make up its mind about whether its Duchenne muscular dystrophy drug, eteplirsen, deserves an accelerated approval....
Prosensa to Present at Upcoming Investor Conferences
GlobeNewswire - Thu Mar 06, 8:24AM CST
Prosensa Holding N.V. (NASDAQ: RNA) announced today announced presentations at upcoming investor conferences. Celia Economides, Senior Director, Investor Relations & Corporate Communications, will present a corporate overview at the ROTH Conference 2014 in Dana Point, California on Tuesday, March 11, at 10:30am (Pacific Time) and at the Barclays Healthcare Conference in Miami, Florida on Wednesday, March 12, at 1:30pm (Eastern Time).
Prosensa Holding N.V. to Webcast Conference Call Discussing Full Year 2013 Financial Results and Corporate Update on March 18, 2014
GlobeNewswire - Wed Mar 05, 9:18AM CST
Prosensa Holding N.V. (NASDAQ: RNA) today announced that the Company will host a conference call and live audio webcast on Tuesday, March 18, 2014 8:00am Eastern Time (1:00pm Central European Time) to report its full year 2013 financial results and provide a corporate update.
Why Sarepta Therapeutics Inc. Might Have a Fighting Chance
Brian Orelli, The Motley Fool - Motley Fool - Tue Mar 04, 5:30PM CST
In November, it looked like Sarepta Therapeutics had very little chance of getting an accelerated approval for its Duchenne muscular dystrophy drug eteplirsen. The company said the Food and Drug Administration did a 180, from being open to...
4 Biotech Stocks Under $10 Moving Higher
at The Street - Wed Feb 26, 5:00AM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
3 Biotech Stocks to Avoid: Amarin, Dendreon, and Prosensa
Leo Sun, The Motley Fool - Motley Fool - Mon Feb 17, 2:37PM CST
In the stock market, everyone loves a great turnaround story. In the biotech sector, where companies can rally or plunge by the double-digits on an FDA approval or rejection, bottom-fishing investors love to search for broken stocks with overlooked...
Shareholder Rights Law Firm Johnson & Weaver, LLP Announces Investigation of Prosensa Holding N.V. and Its Disclosures Related to Experimental Drug Drisapersen
Business Wire - Wed Feb 05, 3:45PM CST
Shareholder rights law firm Johnson & Weaver, LLP has commenced an investigation into whether certain officers and directors of Prosensa Holding N.V. (NASDAQ: RNA) violated state or federal laws. Prosensa is a Dutch biotechnology company engaged in the discovery and development of ribonucleic acid-modulating therapeutics for the treatment of genetic disorders.
Companies Limp Towards a Duchenne Treatment – Is There Hope of a Finish Line?
Amy Ho, The Motley Fool - Motley Fool - Tue Feb 04, 5:30PM CST
Duchenne's muscular dystrophy is a debilitating disease of young males resulting from an early stop sign (nonsense mutation) in an essential muscle protein dystrophin. While only 35,000 patients in the US and Europe are afflicted, the disease is so...
Prosensa to Participate at Upcoming Investor Conferences
GlobeNewswire - Fri Jan 31, 8:17AM CST
Prosensa Holding N.V. (NASDAQ: RNA) announced today that it is schedule to participate at the following investor conferences in February.
